论文部分内容阅读
据一项多中心安慰剂对照Ⅲ期临床研究的结果报道，Immunex公司的注射用米托蒽醌（mltoxantrone，商品名Novantron）用于治疗多发性硬化症（MS）可能是有前途的。在本研究中，194例进展性MS病人静脉注射本品5或12mg／mZ或安慰剂，每三个月1次，治疗2年。与安慰剂组相比，本品组
According to a multicenter placebo-controlled phase III clinical trial, Immunex’s injection of mltoxantrone (Novantron) may be promising for the treatment of multiple sclerosis (MS). In this study, 194 patients with progressive MS were intravenously injected with either 5 or 12 mg / mZ of this product or placebo once every three months for 2 years. Compared with placebo, this product group